Israel Englander’s Nuvectis Pharma NVCT Stock Holding History

Israel Englander’s Portfolio NVCT Stock Details NVCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-31,167	Closed	-$233K	–	6323
2025 Q2	$233K	Sell	31,167 -89,934	-74%	-$816K	﹤0.01%	5298
2025 Q1	$1.18M	Buy	121,101 +91,403	+308%	+$658K	﹤0.01%	4232
2024 Q4	$161K	Sell	29,698 -38,801	-57%	-$243K	﹤0.01%	5375
2024 Q3	$431K	Sell	68,499 -50,960	-43%	-$335K	﹤0.01%	4942
2024 Q2	$756K	Buy	119,459 +79,958	+202%	+$543K	﹤0.01%	4315
2024 Q1	$324K	Buy	39,501 +5,490	+16%	+$46.7K	﹤0.01%	5093
2023 Q4	$284K	Buy	+34,011	New	+$303K	﹤0.01%	4987
2023 Q2	–	Sell	-24,667	Closed	-$323K	–	6514
2023 Q1	$323K	Buy	+24,667	New	+$250K	﹤0.01%	4862
2022 Q2	–	Sell	-42,160	Closed	-$312K	–	7333
2022 Q1	$312K	Buy	+42,160	New	+$293K	﹤0.01%	5501

Other funds holding NVCT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return

BWP

Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

OCM

Occam Crest Management Darien, Connecticut $193M AUM 233.09% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Oppenheimer & Co New York $9.37B AUM 36.4% 1-Year Est. Return

Israel Englander's NVCT Position: Q3 2025 in Review

Israel Englander sold out of Nuvectis Pharma (NVCT) in Q3 2025, closing a stake of 31,167 shares — an estimated $233K sold.

Israel Englander first reported a position in NVCT in Q1 2022 and held it in 9 quarters. The position peaked at $1.18M in Q1 2025. 53 funds tracked by Wall St. Rank hold NVCT as of Q3 2025.

Israel Englander reported no remaining Nuvectis Pharma position as of Q3 2025 after selling out during the quarter.
Israel Englander sold 31,167 Nuvectis Pharma shares in Q3 2025, an estimated $233K.
Israel Englander first reported a position in Nuvectis Pharma in Q1 2022 and held it in 9 quarters.
Israel Englander's Nuvectis Pharma position peaked at $1.18M in Q1 2025.
53 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q3 2025.

Based on Millennium Management's 13F filing for Q3 2025, filed 14 Nov 2025.